Edwards Lifesciences Corp... (EW)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
71.89
0.85 (1.20%)
At close: Jan 15, 2025, 9:55 AM
Edwards Lifesciences Corporation Revenue Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Surgical Heart Valve Therapy Revenue | 240.00M | 264.30M | 266.10M | 248.20M | 246.60M | 256.30M | 248.20M | 224.10M | 219.70M | 228.50M | 220.80M | 221.30M | 217.40M | 237.40M | 213.00M | 204.20M | 203.30M | 160.90M | 193.40M | 205.10M | 204.10M | 217.80M | 214.70M | 207.20M | 184.60M | 190.30M | 179.50M | 204.90M | 195.60M | 207.10M | 199.50M | 189.40M | 190.90M | 198.70M | 195.90M | 196.20M | 187.90M | 204.00M | 196.90M | 206.10M | 203.40M | 214.00M | 202.60M | 207.00M | 191.80M | 204.30M | 198.10M | 197.70M | 185.70M | 200.50M | 203.60M | 256.60M | 246.10M | 263.10M | 244.90M |
Surgical Heart Valve Therapy Revenue Growth | -9.19% | -0.68% | +7.21% | +0.65% | -3.78% | +3.26% | +10.75% | +2.00% | -3.85% | +3.49% | -0.23% | +1.79% | -8.42% | +11.46% | +4.31% | +0.44% | +26.35% | -16.80% | -5.70% | +0.49% | -6.29% | +1.44% | +3.62% | +12.24% | -3.00% | +6.02% | -12.40% | +4.75% | -5.55% | +3.81% | +5.33% | -0.79% | -3.93% | +1.43% | -0.15% | +4.42% | -7.89% | +3.61% | -4.46% | +1.33% | -4.95% | +5.63% | -2.13% | +7.92% | -6.12% | +3.13% | +0.20% | +6.46% | -7.38% | -1.52% | -20.65% | +4.27% | -6.46% | +7.43% | n/a |
Transcatheter Heart Valves Revenue | 1.02B | 1.04B | 1.01B | 979.40M | 960.90M | 991.60M | 947.90M | 867.70M | 862.30M | 906.90M | 881.30M | 871.50M | 857.80M | 901.50M | 791.70M | 776.20M | 744.60M | 594.30M | 742.20M | 762.50M | 700.00M | 677.70M | 597.70M | 592.40M | 557.80M | 584.90M | 551.60M | 519.30M | 481.20M | 487.50M | 539.20M | 432.00M | 410.10M | 418.60M | 367.80M | 334.30M | 296.10M | 281.40M | 268.50M | 267.50M | 267.20M | 219.70M | 189.20M | 183.90M | 172.00M | 182.10M | 169.70M | 161.00M | 123.80M | 145.80M | 121.50M | n/a | n/a | n/a | n/a |
Transcatheter Heart Valves Revenue Growth | -1.47% | +3.05% | +2.91% | +1.93% | -3.10% | +4.61% | +9.24% | +0.63% | -4.92% | +2.90% | +1.12% | +1.60% | -4.85% | +13.87% | +2.00% | +4.24% | +25.29% | -19.93% | -2.66% | +8.93% | +3.29% | +13.38% | +0.89% | +6.20% | -4.63% | +6.04% | +6.22% | +7.92% | -1.29% | -9.59% | +24.81% | +5.34% | -2.03% | +13.81% | +10.02% | +12.90% | +5.22% | +4.80% | +0.37% | +0.11% | +21.62% | +16.12% | +2.88% | +6.92% | -5.55% | +7.31% | +5.40% | +30.05% | -15.09% | +20.00% | n/a | n/a | n/a | n/a | n/a |
Transcatheter Mitral And Tricuspid Therapies Revenue | 91.10M | 83.00M | 72.90M | 56.00M | 52.40M | 47.60M | 41.60M | 31.50M | 29.70M | 27.90M | 27.00M | 25.30M | 22.30M | 22.10M | 16.30M | 13.10M | 12.10M | 6.10M | 10.50M | 7.20M | 9.70M | 7.00M | 4.30M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Transcatheter Mitral And Tricuspid Therapies Revenue Growth | +9.76% | +13.85% | +30.18% | +6.87% | +10.08% | +14.42% | +32.06% | +6.06% | +6.45% | +3.33% | +6.72% | +13.45% | +0.90% | +35.58% | +24.43% | +8.26% | +98.36% | -41.90% | +45.83% | -25.77% | +38.57% | +62.79% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
Quarter | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Europe Revenue | 1.33B | 1.17B | 1.19B | 973.60M | 941.20M | 885.10M | 831.00M | 749.00M | 717.30M | 741.40M | 616.50M | 559.70M | 574.00M | 879.40M |
Europe Revenue Growth | +13.59% | -1.30% | +22.26% | +3.44% | +6.34% | +6.51% | +10.95% | +4.42% | -3.25% | +20.26% | +10.15% | -2.49% | -34.73% | n/a |
Japan Revenue | 452.40M | 473.60M | 528.90M | 460.10M | 444.70M | 396.80M | 350.30M | 309.30M | 246.20M | 270.80M | 243.60M | 294.10M | 283.70M | 567.60M |
Japan Revenue Growth | -4.48% | -10.46% | +14.95% | +3.46% | +12.07% | +13.27% | +13.26% | +25.63% | -9.08% | +11.17% | -17.17% | +3.67% | -50.02% | n/a |
Rest Of World Revenue | 709.20M | 601.40M | 550.20M | 435.80M | 429.40M | 385.60M | 346.40M | 289.70M | 267.30M | 1.05B | 245.80M | 233.70M | 215.30M | n/a |
Rest Of World Revenue Growth | +17.92% | +9.31% | +26.25% | +1.49% | +11.36% | +11.32% | +19.57% | +8.38% | -74.48% | +326.08% | +5.18% | +8.55% | n/a | n/a |
United States Revenue | 3.51B | 3.13B | 2.96B | 2.52B | 2.53B | 2.06B | 1.91B | 1.62B | 1.26B | n/a | 939.60M | 812.10M | 605.60M | n/a |
United States Revenue Growth | +12.01% | +5.72% | +17.73% | -0.63% | +23.23% | +7.74% | +18.07% | +27.94% | n/a | n/a | +15.70% | +34.10% | n/a | n/a |
Operating Expense Breakdown
Quarter | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selling, General, and Administrative Revenue | 421.40M | 450.80M | 489.70M | 478.80M | 439.60M | 468.70M | 436.30M | 411.00M | 377.30M | 409.00M | 370.30M | 424.00M | 364.40M | 374.50M | 330.80M | 338.50M | 307.20M | 274.90M | 307.80M | 347.20M | 306.20M | 308.50M | 280.30M | 288.10M | 269.50M | 274.90M | 256.00M | 266.70M | 244.60M | 243.80M | 229.60M | 233.60M | 229.60M | 228.80M | 212.70M | 222.30M | 212.00M | 213.90M | 202.50M |
Selling, General, and Administrative Revenue Growth | -6.52% | -7.94% | +2.28% | +8.92% | -6.21% | +7.43% | +6.16% | +8.93% | -7.75% | +10.45% | -12.67% | +16.36% | -2.70% | +13.21% | -2.27% | +10.19% | +11.75% | -10.69% | -11.35% | +13.39% | -0.75% | +10.06% | -2.71% | +6.90% | -1.96% | +7.38% | -4.01% | +9.04% | +0.33% | +6.18% | -1.71% | +1.74% | +0.35% | +7.57% | -4.32% | +4.86% | -0.89% | +5.63% | n/a |
Research and Development Revenue | 253.40M | 272.60M | 285.20M | 270.00M | 270.30M | 270.30M | 261.20M | 232.20M | 233.60M | 250.80M | 228.60M | 232.80M | 238.00M | 225.30M | 207.00M | 195.70M | 195.50M | 182.10M | 187.40M | 193.90M | 195.50M | 191.90M | 171.40M | 163.10M | 161.80M | 154.10M | 143.20M | 146.60M | 142.90M | 134.40M | 128.70M | 114.90M | 113.10M | 112.90M | 102.40M | 98.20M | 101.00M | 97.50M | 86.40M |
Research and Development Revenue Growth | -7.04% | -4.42% | +5.63% | -0.11% | n/a | +3.48% | +12.49% | -0.60% | -6.86% | +9.71% | -1.80% | -2.18% | +5.64% | +8.84% | +5.77% | +0.10% | +7.36% | -2.83% | -3.35% | -0.82% | +1.88% | +11.96% | +5.09% | +0.80% | +5.00% | +7.61% | -2.32% | +2.59% | +6.32% | +4.43% | +12.01% | +1.59% | +0.18% | +10.25% | +4.28% | -2.77% | +3.59% | +12.85% | n/a |